## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Valerie J. Ryan, Chienkuo Ronnie Yuan and Guy A. Crosby

Continuation Application of

Application No.: 09/306,530

Filed: May 6, 1999

Title:

Applicant:

Methods for Lowering Viscosity of Glucomannan Compositions, Uses and Compositions

PATENT APPLICATION

DOCKET NO.: 1022.1157-013

Date: Jumany 16, 2004

EXPRESS MAIL LABEL NO. EV 214934391 US

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This I	Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
[]	under 37 CFR 1.97(c) together with either:
	[ ] a Statement under 37 CFR 1.97(e), as checked below, or
	[ ] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[]	under 37 CFR 1.97(d) together with:
	[ ] a Statement under 37 CFR 1.97(e), as checked below, and
	[ ] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
[ ]	under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)
Stater	ment Under 37 CFR 1.97(e)
[]	Each item of information contained in this Information Disclosure Statement was first cited in

any communication from a foreign patent office in a counterpart foreign application not more

than three months prior to the filing of this Information Disclosure Statement; or

[ ]	comm know in the	unication ledge of informa	formation contained in this Information Disclosure Statement was cited in a confrom a foreign patent office in a counterpart foreign application, and, to the the undersigned, after making reasonable inquiry, no item of information contained ation disclosure statement was known to any individual designated in 37 CFR than three months prior to the filing of this Information Disclosure Statement.
State	ment Ur	ider 37 (	CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000
[]	comm was n	unication of receiver	information contained in the Information Disclosure Statement was cited in a on from a foreign patent office in a counterpart application and this communication wed by any individual designated in § 1.56(c) more than thirty days prior to the aformation Disclosure Statement.
[X]	Enclo	sed here	ewith is form PTO-1449:
	[ ]	Copie	s of the cited references are enclosed.
		[ ]	Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
	[X]	Applio	s of the cited references are enclosed except those entered in prior application, U.S. cation No. 09/306,530, to which priority under 35 U.S.C. 120 is claimed. The application contains copies of the cited references.
	[ ]	The li	sted references were cited in the enclosed International Search Report in a expart foreign application.
	[X]	The "c 37 CF	concise explanation" requirement (non-English reference) for reference AT2 under R 1.98(a)(3) is satisfied by:
		[ ]	the explanation provided on the attached sheet.
		[ ]	the explanation provided in the Specification.
		[ ]	submission of the enclosed International Search Report.
		[ ]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
		[X]	the English language abstract filed in U.S. Application No. 09/306,530.

[ ]	Applic	cant requests that the following r	non-published pending appli	cations be considered:
Examiner's Initials				
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		Examiner	Date	_
	[ ]	A copy of each above-cited app	olication, including the curre	nt claims, is enclosed.
	[ ]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.	olication, including the curre on, U.S. Application No. [	nt claims, is enclosed, except ], to which priority under
		is requested to return a copy of re considered with the next offic		plications indicating which
It is re	quested	that the information disclosed h	erein be made of record in the	his application.
Metho	d of pay	ment:		
[ ]		ck for the fee noted above is encl panying Reply. A copy of this S		cluded in the check with the
[ ]	Please	charge Deposit Account 08-038 ed.	0 in the amount of \$[	. A copy of this Statement is
[X]	Please	charge any deficiency in fees an	d credit any overpayment to	Deposit Account 08-0380.
		R	Respectfully submitted,	
		H	IAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.
		· B	Pamela A. Torpey Registration No.: 45,736 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	y

Concord, MA 01742-9133 Dated: January 16, 2004

DTO 1440	REPRODUCED
F10-1449	KERKUDUCED

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

January 16, 2004 (Use several sheets if necessary)

ATTORNEY DOCKET NO. 1022.1157-013		LICATION NO. ntinuation of	509/306,530
FIRST NAMED INVENTOR Valerie J. Ryan, et al.	_	FILING DATE	
EXAMINER	CONFI	RMATION NO.	GROUP

		U.S	S. PATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	5,733,593	03/31/1998	Shelso et al.
	AB	4,894,250	01/16/1990	Musson et al.
	AC	5,603,976	02/18/1997	Share et al.
	AD	5,308,636	05/03/1994	Tye et al.
	AE	4,746,528	05/24/1988	Prest et al.
	AF	4,427,704	01/24/1984	Cheney et al.
	AG	4,844,922	07/04/1989	Uemura et al.
	АН	4,582,714	04/15/1986	Ford et al.
	AI			
	AJ			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

January 16, 2004 (Use several sheets if necessary)

			Direct 2 of
ATTORNEY DOCKET NO. 1022.1157-013		PLICATION NO.	f 09/306,530
FIRST NAMED INVENTOR Valerie J. Ryan, et al.		FILING DATE	
EXAMINER	CONF	IRMATION NO	GROUP

		FOREIGN PATENT D	OCUMENTS		
	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANS YES	LATION NO
AL	0 898 900 A2	03/03/1999	Societe Des Produits Nestle S.A.		
AM	WO 90/15544	12/27/1990	FMC Corporation		
AN	EP 0 185 511 A	06/25/1986	Mars G.B. Limited		
AM					
AN					
AO					
AP					
AQ					
AL2				U. U	
AM2					1212
AN2					
AO2					
AP2					
AQ2		,		···.	
AL3	1				
AM3					
AN3		· · · · · · · · · · · · · · · · · · ·			
AO3				• • • • • • • • • • • • • • • • • • • •	
AP3					
AQ3					
AL4					
AM4					
AN4		<u> </u>		. <u></u> .	
AO4					
AP4				· · · · · · · · · · · · · · · · · · ·	
AQ4					

EXAMINER	DATE CONSIDERED
EXAMINER	

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 1022.1157-013		PLICATION NO.  ontinuation of	f 09/306,530
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Valerie J. Ryan, et al.  FILING DATE		FILING DATE	
January 16, 2004 (Use several sheets if necessary)	EXAMINER	CONF	IRMATION NO.	GROUP

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AR	Crosby, G., "Nutritional Flour Power", Ingredients Health & Nutrition, 5:(1999).
AS	A. Arvill and L. Bodin, "Effect of Short-term Ingestion of Konjac Glucomannan on Serum Cholesterol in Healthy Men", Am. J. Clin. Nutr., 61:585-599 (1995).
AT	Jenkins et al., "Dietary Fibres, Fibre Analoques, and Glucose Tolerance: Importance of Viscosity", British Medical Journal, 1:1392-1394 (May 27, 1978).
AU	Yoshimura et al., "Effects of Konjac-Glucomannan on the Gelatinization and Retrogradation of Corn Starch As Determined by Rheology and Differential Scanning Calorimetry", J. Agric. Food Chem, 44(10):2970-2976 (1996).
AV	Ide et al., "Contrasting Effects of Water-Soluble and Water-Insoluble Dietary Fibers on Bile Acid Conjugation and Taurine Metabolism in the Rat", Lipids, 25(6):335-340(1990).
AW	Nutricol® Konjac, FMC (1994).
AX	LaBell, F., "Flour from Oriental Root Yields Heat-Stable Gels, Provides High Viscosity", Food Processing, November 1989.
AY	Tye, R., "Konjac Flour: Properties and Applications", Food Technology, March 1991.
AZ	S.E. Davis and B.A. Lewis, "Physiological Effects of Mannans, Galactomannans, and Glucomannans", <i>Physiological Effects of Food Carbohydrates</i> , 296-311 (1975).
AR2	Shimisu, H. et al., "Effects of Dietary Konjac Mannan on Serum and Liver Cholesterol Levels and Biliary Bile Acid Composition in Hamsters", J. Pharmacobio-Dyn., 14:371-375 (1991).
AS2	Doi, K., "Effect of Konjac Fibre(glucomannan) on Glucose and Lipids", European Journal of Clinical Nutrition, 49(3):S190-S197 (1995).
AT2	"Physiological Active Glucomannan Drink Mix Glucomannan Granule Water Liquefy Obtain Konjak Paste Enzyme Heat Sterile", <i>Database WPI</i> , 323042 (1993) (Japan Patent Abstract: JP5199856).
AU2	

EXAMINER	DATE CONSIDERED	